

JC13 Recd PCT/PTO 01 APR 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re United States Patent Application of:)	Docket No.:	4240-119
Applicant(s):)	Examiner:	Not Yet Assigned
Application No.:)	Art Unit:	Not Yet Assigned
Int'l Filing Date:)	Customer No.:	
Priority Date:)		
Title:)		

SUNG, Moon-Hee, et al

New U.S. National Stage Application of PCT International Application No. PCT/KR2003/002163

17 October 2003


17 October 2002 (Korean Patent Application No. 10-2002-0063378)

VECTOR FOR ANTI-HPV VACCINE AND TRANSFORMED MICROORGANISM BY THE VECTOR

23448

EXPRESS MAIL CERTIFICATE

I hereby certify that I am mailing the attached documents to the Commissioner for Patents on the date specified, in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, and Express Mailed under the provisions of 37 CFR 1.10.


Candace White

April 1, 2005

Date

EO 004 386 103 US
Express Mail Label Number

INFORMATION DISCLOSURE STATEMENT


Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Sir:

Pursuant to 37 C.F.R. §1.56, the attention of the Patent and Trademark Office is hereby directed to the reference(s) listed on the attached PTO/SB/08A. One copy of each reference is attached. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the reference(s) be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

- ☒ 1. This Information Disclosure Statement is being filed within three months of the U.S. filing date OR before the mailing date of a first Office Action on the merits. No certification or fee is required.
- ☐ 2. This Information Disclosure Statement is being filed more than three months after the U.S. filing date AND after the mailing date of the first Office Action on the merits, but before the mailing date of a Final Rejection or Notice of Allowance.
- ☐ a. I hereby certify that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. §1.97(e)(1).
- ☐ b. I hereby certify that no item of information in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. §1.97(e)(2).
- ☐ c. Attached is our check no. _____ in the amount of \$_____ in payment of the fee under 37 C.F.R. §1.17(p). Please credit or debit Deposit Account No. _____ as needed to ensure consideration of the disclosed information. Two duplicate copies of this paper are attached.
- ☐ 3. This Information Disclosure Statement is being filed more than three months after the U.S. filing date and after the mailing date of a Final Rejection or Notice of Allowance, but before payment of the Issue Fee. Applicant(s) hereby petition(s) that the Information Disclosure Statement be considered. Attached is our check no. _____ in the amount of \$180.00 in payment of the petition fee under 37 C.F.R. §1.17(p). Please credit or debit Deposit Account No. _____ as needed to ensure consideration of the disclosed information. Two duplicate copies of this paper are attached.
- ☐ a. I hereby certify that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. §1.97(e)(1).
- ☐ b. I hereby certify that no item of information in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. §1.97(e)(2).

Respectfully submitted,



Steven J. Hultquist
Reg. No. 28,021
Attorney for Applicants

10/530083

JC13 Rec'd PTO 01 APR 2005

INTELLECTUAL PROPERTY/
TECHNOLOGY LAW
Telephone: (919) 419-9350
Fax: (919) 419-9354
Attorney Ref: 4240-119

Sheet 1 of 1

4240-119

¹ All the foreign patents and publications that are not written in English language are accompanied by their respective English abstracts, which constitute concise explanation of relevance of the non-English patents and publications that satisfy the requirements of 37 C.F.R. §1.98(a)(3)(i), according to MPEP 609 III A(3).

10/530083

1013 Rec'd 01 APR 2005

INFORMATION DISCLOSURE STATEMENT BY APPLICANT Sheet 1 of 1	COMPLETE IF KNOWN	
	Application Number	Unassigned
	Filing Date	April 1, 2005
	First Named Inventor	SUNG, et al.
	Art Unit	Unassigned
	Examiner Name	Unassigned
	Attorney Docket Number	4240-119

NON-PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	AC	CHARBIT, et al., <i>J. Immunol.</i> , 139:1658 (1987).	
	AD	AGTERBERG, et al., <i>Vaccine</i> , 8:85 (1990).	
	AE	FELICI, et al., <i>J. Mol. Biol.</i> , 222:301 (1991).	
	AF	FUCHS, et al., <i>Bio/Technology</i> , 9:1369 (1991).	
	AG	HEDEGAARD, et al., <i>Gene</i> , 85:115 (1989).	
	AH	JUNG, et al., <i>Nat. Biotechnol.</i> , 16:576 (1998).	
	AI	JUNG, et al., <i>Enzyme Microb. Technol.</i> , 22(5):348 (1998).	
	AJ	LEE, et al., <i>Nat. Biotechnol.</i> , 18:645 (2000).	
	AK	KORNACKER, et al., <i>Mol. Microb.</i> , 4:1101 (1990).	
	AL	PFISTER, H., et al., <i>Adv. Cancer Res.</i> , 48:113 (1987).	
	AM	PISANI et al., <i>Int. J. Cancer</i> , 55:891 (1993).	

Examiner signature		Date Considered	
--------------------	--	-----------------	--

*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

² Applicant is to place a check mark here if English Translation is attached. All the foreign patents and publications that are not written in English language are accompanied by their respective English abstracts, which constitute concise explanation of relevance of the non-English patents and publications that satisfy the requirements of 37 C.F.R. §1.98(a)(3)(i), according to MPEP 609 III A(3).

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Sheet 1 of 1

COMPLETE IF KNOWN

Application Number	Unassigned
Filing Date	April 1, 2005
First Named Inventor	SUNG, et al.
Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	4240-119

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume issue number(s), publisher, city and/or country where published	T ²
	AN	KOUTSKY, et al., <i>N. Engl. J. of Med.</i> , 347(21):1645 (2002). ✕	
	AO	HAGENSEE, et al., <i>J. Virol.</i> , 67:315 (1993). ✕	
	AP	SCHILLER, et al., <i>Seminars in Cancer Biol.</i> , 7:373 (1996). ✕	
	AQ	BUBENIK, J., et al., <i>Neoplasma</i> , 49:285 (2002). ✕	
	AR	GAO, et al., <i>J. Gen. Virol.</i> , 75:157 (1994). ✕	
	AS	MENEGUZZI, et al., <i>Virology</i> , 181:62 (1991). ✕	
	AT	MOSS, B. et al., <i>Proc. Natl. Acad. Sci. USA</i> , 93:11341 (1996). ✕	
	AU	RESSING, et al., <i>J. Immunol.</i> , 154:5934 (1995). ✕	
	AV	THAVALA, et al., <i>Proc. Natl. Acad. Sci. USA</i> , 92:3358 (1995). ✕	

Examiner signature		Date Considered	
--------------------	--	-----------------	--

*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

² Applicant is to place a check mark here if English Translation is attached. All the foreign patents and publications that are not written in English language are accompanied by their respective English abstracts, which constitute concise explanation of relevance of the non-English patents and publications that satisfy the requirements of 37 C.F.R. §1.98(a)(3)(i), according to MPEP 609 III A(3).